Atomoxetine

Atomoxetine
Clinical data
Trade namesStrattera, others
Other namesATX; Tomoxetine; LY-135252; LY135252; (R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine
AHFS/Drugs.comMonograph
MedlinePlusa603013
License data
Pregnancy
category
  • AU: B3
Routes of
administration
Oral
Drug classNorepinephrine reuptake inhibitor (NRI)
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • BR: Class C1 (Other controlled substances)
  • CA: ℞-only
  • NZ: Prescription only
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Pharmacokinetic data
Bioavailability2D6Tooltip CYP2D6 EMsTooltip extensive metabolizers: 94%
2D6Tooltip CYP2D6 PMsTooltip poor metabolizers: 63%
Protein bindingATX: 98.7%
4-OH-ATX: 66.6%
N-DM-ATX: 99.1%
MetabolismLiver: ring hydroxylation (CYP2D6, others), benzylic hydroxylation, N-demethylation (CYP2C19), glucuronidation (UGTsTooltip UDP-glucuronyltransferases)
Metabolites• 4-Hydroxyatomoxetine
• N-Desmethylatomoxetine
• 2-Hydroxymethylatomoxetine
• N-Desmethyl-4-hydroxyatomoxetine
• Glucuronide conjugates
Onset of action1–2 hours (TmaxTooltip time to peak levels)
Elimination half-life2D6Tooltip CYP2D6 EMsTooltip extensive metabolizers: 4.5–5.3 h
2D6Tooltip CYP2D6 PMsTooltip poor metabolizers: 19–22 h
Excretion2D6Tooltip CYP2D6 EMsTooltip extensive metabolizers: urine (>96%), feces (1–2%)
2D6Tooltip CYP2D6 PMsTooltip poor metabolizers: urine (80%), feces (13–22%)
Identifiers
  • (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.120.306
Chemical and physical data
FormulaC17H21NO
Molar mass255.361 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC=C1)O[C@H](CCNC)C2=CC=CC=C2
  • InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1 checkY
  • Key:VHGCDTVCOLNTBX-QGZVFWFLSA-N checkY
 X markNcheckY (what is this?)  (verify)

Atomoxetine, sold under the brand name Strattera, is a selective norepinephrine reuptake inhibitor (SNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, cognitive disengagement syndrome (CDS). It may be used alone or along with psychostimulant medication. It enhances the executive functions of self-motivation, sustained attention, inhibition, working memory, reaction time, and emotional self-regulation. Use of atomoxetine is only recommended for those who are at least six years old. It is taken orally. The effectiveness of atomoxetine is comparable to the commonly prescribed stimulant medication methylphenidate.

Common side effects of atomoxetine include abdominal pain, decreased appetite, nausea, feeling tired, and dizziness. Serious side effects may include angioedema, liver problems, stroke, psychosis, heart problems, suicide, and aggression. There is a lack of data regarding its safety during pregnancy; as of 2019, its safety during pregnancy and for use during breastfeeding is not certain.

It was approved for medical use in the United States in 2002. In 2023, it was the 161st most commonly prescribed medication in the United States, with more than 3 million prescriptions.